HLA-DRB10401 and HLA-DRB10408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis
The formation of antibodies to interferon-beta (IFN-beta), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resol...
Saved in:
| Published in | American journal of human genetics Vol. 83; no. 2; pp. 219 - 227 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chicago, IL
University of Chicago Press
01.08.2008
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The formation of antibodies to interferon-beta (IFN-beta), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resolution HLA class I and II typing we identified two HLA class II alleles associated with the development of antibodies to IFN-beta. In two independent continuous and binary-trait association studies, HLA-DRB1*0401 and HLA-DRB1*0408 (odds ratio: 5.15)--but not other HLA alleles--were strongly associated with the development of binding and neutralizing antibodies to IFN-beta. The associated HLA-DRB1*04 alleles differ from nonassociated HLA-DRB1*04 alleles by a glycine-to-valine substitution in position 86 of the epitope-binding alpha-helix of the HLA class II molecule. The peptide-binding motif of HLA-DRB1*0401 and *0408 might promote binding and presentation of an immunogenic peptide, which may eventually break T cell tolerance and facilitate antibody development to IFN-beta. In summary, we identified genetic factors determining the immunogenicity of IFN-beta, a protein-based disease-modifying agent for the treatment of MS. |
|---|---|
| AbstractList | The formation of antibodies to interferon-beta (IFN-beta), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resolution HLA class I and II typing we identified two HLA class II alleles associated with the development of antibodies to IFN-beta. In two independent continuous and binary-trait association studies, HLA-DRB1*0401 and HLA-DRB1*0408 (odds ratio: 5.15)--but not other HLA alleles--were strongly associated with the development of binding and neutralizing antibodies to IFN-beta. The associated HLA-DRB1*04 alleles differ from nonassociated HLA-DRB1*04 alleles by a glycine-to-valine substitution in position 86 of the epitope-binding alpha-helix of the HLA class II molecule. The peptide-binding motif of HLA-DRB1*0401 and *0408 might promote binding and presentation of an immunogenic peptide, which may eventually break T cell tolerance and facilitate antibody development to IFN-beta. In summary, we identified genetic factors determining the immunogenicity of IFN-beta, a protein-based disease-modifying agent for the treatment of MS.The formation of antibodies to interferon-beta (IFN-beta), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resolution HLA class I and II typing we identified two HLA class II alleles associated with the development of antibodies to IFN-beta. In two independent continuous and binary-trait association studies, HLA-DRB1*0401 and HLA-DRB1*0408 (odds ratio: 5.15)--but not other HLA alleles--were strongly associated with the development of binding and neutralizing antibodies to IFN-beta. The associated HLA-DRB1*04 alleles differ from nonassociated HLA-DRB1*04 alleles by a glycine-to-valine substitution in position 86 of the epitope-binding alpha-helix of the HLA class II molecule. The peptide-binding motif of HLA-DRB1*0401 and *0408 might promote binding and presentation of an immunogenic peptide, which may eventually break T cell tolerance and facilitate antibody development to IFN-beta. In summary, we identified genetic factors determining the immunogenicity of IFN-beta, a protein-based disease-modifying agent for the treatment of MS. The formation of antibodies to interferon-beta (IFN-beta), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical practice. These antibodies may neutralize the biological effects of the protein drug, potentially decreasing its therapeutic effects. By high-resolution HLA class I and II typing we identified two HLA class II alleles associated with the development of antibodies to IFN-beta. In two independent continuous and binary-trait association studies, HLA-DRB1*0401 and HLA-DRB1*0408 (odds ratio: 5.15)--but not other HLA alleles--were strongly associated with the development of binding and neutralizing antibodies to IFN-beta. The associated HLA-DRB1*04 alleles differ from nonassociated HLA-DRB1*04 alleles by a glycine-to-valine substitution in position 86 of the epitope-binding alpha-helix of the HLA class II molecule. The peptide-binding motif of HLA-DRB1*0401 and *0408 might promote binding and presentation of an immunogenic peptide, which may eventually break T cell tolerance and facilitate antibody development to IFN-beta. In summary, we identified genetic factors determining the immunogenicity of IFN-beta, a protein-based disease-modifying agent for the treatment of MS. |
| Author | GRUMMEL, Verena BERTHELE, Achim DEISENHAMMER, Florian CEPOK, Sabine HARTUNG, Hans-Peter WASMUTH, Ralf HEMMER, Bernhard HACKERMUELLER, Jörg HOFFMANN, Steve LEHMANN-HORN, Klaus STADLER, Peter F |
| Author_xml | – sequence: 1 givenname: Steve surname: HOFFMANN fullname: HOFFMANN, Steve organization: Interdisciplinary Center for Bioinformatics and Department of Bioinformatics, University Leipzig, 04107 Leipzig, Germany – sequence: 2 givenname: Sabine surname: CEPOK fullname: CEPOK, Sabine organization: Department of Neurology, Klinikum Rechts der Isar, 81675 München, Germany – sequence: 3 givenname: Bernhard surname: HEMMER fullname: HEMMER, Bernhard organization: Department of Neurology, Klinikum Rechts der Isar, 81675 München, Germany – sequence: 4 givenname: Verena surname: GRUMMEL fullname: GRUMMEL, Verena organization: Department of Neurology, Klinikum Rechts der Isar, 81675 München, Germany – sequence: 5 givenname: Klaus surname: LEHMANN-HORN fullname: LEHMANN-HORN, Klaus organization: Department of Neurology, Klinikum Rechts der Isar, 81675 München, Germany – sequence: 6 givenname: Jörg surname: HACKERMUELLER fullname: HACKERMUELLER, Jörg organization: Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany – sequence: 7 givenname: Peter F surname: STADLER fullname: STADLER, Peter F organization: Interdisciplinary Center for Bioinformatics and Department of Bioinformatics, University Leipzig, 04107 Leipzig, Germany – sequence: 8 givenname: Hans-Peter surname: HARTUNG fullname: HARTUNG, Hans-Peter organization: Department of Neurology, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany – sequence: 9 givenname: Achim surname: BERTHELE fullname: BERTHELE, Achim organization: Department of Neurology, Klinikum Rechts der Isar, 81675 München, Germany – sequence: 10 givenname: Florian surname: DEISENHAMMER fullname: DEISENHAMMER, Florian organization: Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria – sequence: 11 givenname: Ralf surname: WASMUTH fullname: WASMUTH, Ralf organization: Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus and DKMS Life Science Lab, 01307 Dresden, Germany |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20562671$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18656179$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0M9uEzEQBnALFdG08AIckC9w22Vsr_8dl7bQSkFIUM6Rs55NHDneZe0U5R36NDwIz8RKBMSN00jf_PSNNBfkLA0JCXnJoGbA1Ntd7XbbTc0BTA26BlBPyIJJoSulQJ6RBQDwynKrz8lFzjsAxgyIZ-ScGSUV03ZBHm-XbXX9-R2DBhh1ydN_AkPbCemXMg1pE4-0zXnogivo6fdQtrRskV7jA8Zh3GMqdOhpm0pYDz5gpm7jQsqF3qWCU49zR_XzB73f4uTGIw2JfjzEEsY4H-jivM4hPydPexczvjjNS_L1_c391W21_PTh7qpdViMzslROIrfe-Y4phmtjeqV7LhtvlVF9z5o1R-15YzrhpNTKN4w72ynLnVFCCCsuyZvfveM0fDtgLqt9yB3G6BIOh7xSVhirmPgv5MCF1VrO8NUJHtZ79KtxCns3HVd_Hj2D1yfgcudiP7nUhfzXcZCKK83EL3Fyjm0 |
| CODEN | AJHGAG |
| ContentType | Journal Article |
| Copyright | 2008 INIST-CNRS |
| Copyright_xml | – notice: 2008 INIST-CNRS |
| DBID | IQODW CGR CUY CVF ECM EIF NPM 7T5 8FD FR3 H94 P64 RC3 7X8 |
| DOI | 10.1016/j.ajhg.2008.07.006 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Genetics Abstracts Immunology Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1537-6605 |
| EndPage | 227 |
| ExternalDocumentID | 18656179 20562671 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --Z -~X .55 .GJ 0R~ 123 1~5 23M 2WC 34R 3O- 4.4 41~ 457 4G. 53G 5GY 62- 6J9 7-5 85S AAEDT AAEDW AAFWJ AAIKJ AAKRW AALRI AAMRU AAQXK AAVLU AAWTL AAXUO AAYWO ABDGV ABJNI ABMAC ABOCM ABWVN ACGFO ACGFS ACGOD ACKIV ACNCT ACPRK ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN ADXHL AENEX AEUPX AEXQZ AFPUW AFRAH AFTJW AGCDD AGCQF AGHFR AGKMS AGQPQ AHMBA AI. AIGII AITUG AKAPO AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP ASPBG AVWKF AZFZN BAWUL C1A CS3 D0L DIK E3Z EBS ECV EFKBS EJD F5P FA8 FCP FDB FEDTE FGOYB GX1 HVGLF HYE HZ~ IH2 IHE IQODW IXB JIG KQ8 L7B M41 MVM NEJ O-L O9- OHT OK1 OZT P2P PQQKQ R2- RIG RNS ROL RPM RPZ SES SJN SSZ TN5 TR2 TWZ UHB UKR UNMZH UPT VH1 WH7 WOQ X7M XOL ZCA ZCG ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 8FD FR3 H94 P64 RC3 7X8 |
| ID | FETCH-LOGICAL-p185t-a5e29dadc161eb88f67f254d9686ff14b2e7d248c3a5576d412a9c692a8633393 |
| ISSN | 0002-9297 1537-6605 |
| IngestDate | Thu Jul 10 19:01:04 EDT 2025 Tue Aug 05 10:10:35 EDT 2025 Mon Jul 21 06:01:45 EDT 2025 Mon Jul 21 09:11:36 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Human HLA-System Therapy Nervous system diseases Multiple sclerosis Antibody Major histocompatibility system Cytokine Inflammatory disease Association Treatment Central nervous system disease Beta interferon Development Genetics Class I histocompatibility antigen |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-p185t-a5e29dadc161eb88f67f254d9686ff14b2e7d248c3a5576d412a9c692a8633393 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 18656179 |
| PQID | 20239775 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_69389613 proquest_miscellaneous_20239775 pubmed_primary_18656179 pascalfrancis_primary_20562671 |
| PublicationCentury | 2000 |
| PublicationDate | 2008-Aug |
| PublicationDateYYYYMMDD | 2008-08-01 |
| PublicationDate_xml | – month: 08 year: 2008 text: 2008-Aug |
| PublicationDecade | 2000 |
| PublicationPlace | Chicago, IL |
| PublicationPlace_xml | – name: Chicago, IL – name: United States |
| PublicationTitle | American journal of human genetics |
| PublicationTitleAlternate | Am J Hum Genet |
| PublicationYear | 2008 |
| Publisher | University of Chicago Press |
| Publisher_xml | – name: University of Chicago Press |
| References | 9196329 - Trends Genet. 1997 Jun;13(6):234-9 11164900 - J Neuroimmunol. 2001 Feb 15;113(2):171-84 1574800 - Tissue Antigens. 1992 Feb;39(2):68-73 1926129 - Tissue Antigens. 1991 Jul;38(1):1-15 16890892 - Autoimmun Rev. 2006 Jul;5(6):389-98 15476870 - Virology. 2004 Nov 10;329(1):11-7 8124728 - Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77 15283985 - Trends Biotechnol. 2004 Aug;22(8):406-10 18087043 - Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20896-901 12501870 - Clin Ther. 2002 Nov;24(11):1720-40; discussion 1719 12119747 - Nat Rev Drug Discov. 2002 Jun;1(6):457-62 16557259 - Nat Rev Immunol. 2006 Apr;6(4):271-82 14747002 - Lancet Neurol. 2004 Feb;3(2):104-10 6370760 - Diabetologia. 1984 Feb;26(2):138-41 14638976 - Neurology. 2003 Nov 25;61(10):1444-6 17660530 - N Engl J Med. 2007 Aug 30;357(9):851-62 14529316 - Mol Diagn. 2003;7(1):17-25 11791212 - Am J Hum Genet. 2002 Feb;70(2):425-34 15958824 - Nephrol Dial Transplant. 2005 Jun;20 Suppl 6:vi3-9 15264108 - J Neurol. 2004 Jun;251 Suppl 2:II15-II24 16460651 - Hum Genomics. 2006 Jan;2(4):258-65 9520453 - Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3833-8 17845076 - PLoS Genet. 2007 Sep;3(9):1607-13 17337334 - Biotechnol Adv. 2007 May-Jun;25(3):325-31 14568740 - Lancet. 2003 Oct 11;362(9391):1184-91 15963443 - Lancet Neurol. 2005 Jul;4(7):403-12 12892961 - Lancet. 2003 Jul 26;362(9380):293-4 Am J Hum Genet. 2008 Oct;83(4):541. 17560120 - Semin Immunol. 2007 Aug;19(4):262-71 10746785 - Tissue Antigens. 2000 Feb;55(2):140-8 15930013 - Hum Mol Genet. 2005 Jul 15;14(14):2019-26 17884403 - Eur J Pharm Biopharm. 2008 Mar;68(3):496-502 8244255 - Hepatology. 1993 Dec;18(6):1319-25 16261173 - Nat Rev Immunol. 2005 Nov;5(11):853-65 |
| References_xml | – reference: 15963443 - Lancet Neurol. 2005 Jul;4(7):403-12 – reference: 16261173 - Nat Rev Immunol. 2005 Nov;5(11):853-65 – reference: 8244255 - Hepatology. 1993 Dec;18(6):1319-25 – reference: 17845076 - PLoS Genet. 2007 Sep;3(9):1607-13 – reference: 18087043 - Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20896-901 – reference: 10746785 - Tissue Antigens. 2000 Feb;55(2):140-8 – reference: 15476870 - Virology. 2004 Nov 10;329(1):11-7 – reference: 14638976 - Neurology. 2003 Nov 25;61(10):1444-6 – reference: 15930013 - Hum Mol Genet. 2005 Jul 15;14(14):2019-26 – reference: 17560120 - Semin Immunol. 2007 Aug;19(4):262-71 – reference: 15283985 - Trends Biotechnol. 2004 Aug;22(8):406-10 – reference: 14529316 - Mol Diagn. 2003;7(1):17-25 – reference: 9196329 - Trends Genet. 1997 Jun;13(6):234-9 – reference: 14568740 - Lancet. 2003 Oct 11;362(9391):1184-91 – reference: 6370760 - Diabetologia. 1984 Feb;26(2):138-41 – reference: 17337334 - Biotechnol Adv. 2007 May-Jun;25(3):325-31 – reference: 15958824 - Nephrol Dial Transplant. 2005 Jun;20 Suppl 6:vi3-9 – reference: 8124728 - Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-77 – reference: 17884403 - Eur J Pharm Biopharm. 2008 Mar;68(3):496-502 – reference: 15264108 - J Neurol. 2004 Jun;251 Suppl 2:II15-II24 – reference: 11791212 - Am J Hum Genet. 2002 Feb;70(2):425-34 – reference: 1926129 - Tissue Antigens. 1991 Jul;38(1):1-15 – reference: - Am J Hum Genet. 2008 Oct;83(4):541. – reference: 9520453 - Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3833-8 – reference: 17660530 - N Engl J Med. 2007 Aug 30;357(9):851-62 – reference: 16557259 - Nat Rev Immunol. 2006 Apr;6(4):271-82 – reference: 1574800 - Tissue Antigens. 1992 Feb;39(2):68-73 – reference: 11164900 - J Neuroimmunol. 2001 Feb 15;113(2):171-84 – reference: 14747002 - Lancet Neurol. 2004 Feb;3(2):104-10 – reference: 16890892 - Autoimmun Rev. 2006 Jul;5(6):389-98 – reference: 12119747 - Nat Rev Drug Discov. 2002 Jun;1(6):457-62 – reference: 12501870 - Clin Ther. 2002 Nov;24(11):1720-40; discussion 1719 – reference: 16460651 - Hum Genomics. 2006 Jan;2(4):258-65 – reference: 12892961 - Lancet. 2003 Jul 26;362(9380):293-4 |
| SSID | ssj0011803 |
| Score | 2.2701275 |
| Snippet | The formation of antibodies to interferon-beta (IFN-beta), a protein-based disease-modifying agent for multiple sclerosis (MS), is a problem in clinical... |
| SourceID | proquest pubmed pascalfrancis |
| SourceType | Aggregation Database Index Database |
| StartPage | 219 |
| SubjectTerms | Adolescent Adult Aged Alleles Biological and medical sciences Computational Biology - methods Female Fundamental and applied biological sciences. Psychology Gene Expression Regulation General aspects. Genetic counseling Genetics of eukaryotes. Biological and molecular evolution HLA Antigens - chemistry HLA-DR Antigens - metabolism HLA-DRB1 Chains Humans Interferon-beta - immunology Interferon-beta - metabolism Male Medical genetics Medical sciences Middle Aged Molecular and cellular biology Multiple Sclerosis - genetics Multiple Sclerosis - immunology Multiple Sclerosis - metabolism Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology |
| Title | HLA-DRB10401 and HLA-DRB10408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/18656179 https://www.proquest.com/docview/20239775 https://www.proquest.com/docview/69389613 |
| Volume | 83 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db5swFLWiTpP2Mu172Ufnh_WpoooNGPOYZERsbdKpaqW-RQZMmmqCKiGV2t-wX7MfMu0n7RqD43bpvl5QhAhf9-B7jn18jdB70hMkyAhxpGDM8dxMOJCGpJOnTPp5FgZE1tU-Jyw-8T6d-qedzg_LtbSqkr30euO8kv-JKuyDuKpZsv8QWXNS2AG_Ib6whQjD9q9iHB_0nQ9HA9A6PVKPAlg7-G5_oWyCi7KYfbkyYWjd5opvWoahmpAW1TwplatwV8zEHHij7i_MJZzD2RlGOwOqHBqqCoHqJhkbLyLcFiTb-dJmumYoyKpNoRcEhMdRMycNmY8PR6NxfzJpTGeXBmrD6PPhvu62Tqzh_zgaj7V_YyAXRVsWoDYRHUGOiA5q766axihu9Glw46irrPq4v_OktG05kLvAbsv1ojgNZumGhlnneKrrEfySPnRPxvmeOD-bNT5bVeFyQ63uWznUOBupIpRMFTW4R0G41CL_474Z1yK857aCTN17M41LOw5vX1X5dMUSPtVcr7FytwiqydDxI_SwUTG4ryH5GHVk8QTd1-uaXj1FX21gYgAmtoEJf5O4BSZeAxMrYGIAJraAicscr4GJG2BiC5jfv-EGlHhe4BaU2IDyGToZRcfD2GmW_XAugDxWjvAlDTORpSBGZMJ5zoKc-l4WMs7ynHgJlUFGPZ66wge1nHmEijBlIRWcua4bus_RVlEW8iXCPcn9RIbAaqXwZM9NghTkuqqBKIAFJKKLtm-84emFLvEybcPYRe_aVz6FdlcNpolClqslHEGVdvLvPoKFIAaALXfRCx0rc3bCQUVBJnz1p8u_Rg_Wn8cbtFUtVvItkOAq2a5x9RMgXLGH |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HLA-DRB10401+and+HLA-DRB10408+Are+Strongly+Associated+with+the+Development+of+Antibodies+against+Interferon-%CE%B2+Therapy+in+Multiple+Sclerosis&rft.jtitle=American+journal+of+human+genetics&rft.au=HOFFMANN%2C+Steve&rft.au=CEPOK%2C+Sabine&rft.au=HEMMER%2C+Bernhard&rft.au=GRUMMEL%2C+Verena&rft.date=2008-08-01&rft.pub=University+of+Chicago+Press&rft.issn=0002-9297&rft.volume=83&rft.issue=2&rft.spage=219&rft.epage=227&rft_id=info:doi/10.1016%2Fj.ajhg.2008.07.006&rft.externalDBID=n%2Fa&rft.externalDocID=20562671 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9297&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9297&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9297&client=summon |